Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib

[1]  A. Bezjak,et al.  Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus? , 2022, International journal of radiation oncology, biology, physics.

[2]  K. Xie,et al.  Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer , 2022, Journal of the National Cancer Institute.

[3]  Jinming Yu,et al.  An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[5]  J. Cadranel,et al.  Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[7]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[8]  S. Vinod,et al.  A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II) , 2016, BMC Cancer.

[9]  B. Han,et al.  First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Joe Y. Chang,et al.  Radiation Pneumonitis in Patients with Non–Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[12]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.